Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
3.180
-0.040 (-1.24%)
At close: Sep 1, 2026, 4:00 PM EDT
3.150
-0.030 (-0.94%)
After-hours: Sep 1, 2026, 7:59 PM EDT
Myriad Genetics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 806.6 | 824.5 | 837.6 | 753.2 | 678.4 | 690.6 | |
Revenue Growth | -3.16% | -1.56% | 11.21% | 11.03% | -1.77% | 23.99% |
Cost of Revenue | 251.4 | 247.9 | 252.2 | 236.2 | 202 | 197.6 |
Gross Profit | 555.2 | 576.6 | 585.4 | 517 | 476.4 | 493 |
Selling, General & Admin | 539.9 | 537.6 | 560 | 572.9 | 514.7 | 537.8 |
Research & Development | 105.8 | 106.8 | 113.4 | 88.7 | 85.4 | 81.9 |
Operating Expenses | 645.7 | 644.4 | 673.4 | 661.6 | 600.1 | 619.7 |
Operating Income | -90.5 | -67.8 | -88 | -144.6 | -123.7 | -126.7 |
Interest Expense | -16.4 | -10.5 | -2.8 | -2.9 | -3.2 | -6.6 |
Interest & Investment Income | 2.4 | 1.8 | 1.7 | 2.5 | 2.6 | 0.7 |
Other Non Operating Income (Expenses) | 0.8 | 0.8 | 1.1 | -4.4 | 0.6 | -0.6 |
EBT Excluding Unusual Items | -103.7 | -75.7 | -88 | -149.4 | -123.7 | -133.2 |
Impairment of Goodwill | -4.5 | -234.7 | - | - | -16.9 | -1.8 |
Gain (Loss) on Sale of Assets | - | - | -13.8 | - | - | 151.6 |
Asset Writedown | -3.6 | -84.7 | -43 | - | - | - |
Legal Settlements | - | - | 21.3 | -112.8 | - | -62 |
Other Unusual Items | - | - | - | - | - | -11.7 |
Pretax Income | -111.8 | -395.1 | -123.5 | -262.2 | -140.6 | -57.1 |
Income Tax Expense | 0.8 | -29.2 | 3.8 | 1.1 | -28.6 | -29.9 |
Earnings From Continuing Operations | -112.6 | -365.9 | -127.3 | -263.3 | -112 | -27.2 |
Net Income | -112.6 | -365.9 | -127.3 | -263.3 | -112 | -27.2 |
Net Income to Common | -112.6 | -365.9 | -127.3 | -263.3 | -112 | -27.2 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 94 | 93 | 91 | 83 | 81 | 78 |
Shares Outstanding (Diluted) | 94 | 93 | 91 | 83 | 81 | 78 |
Shares Change | 2.46% | 2.21% | 9.42% | 2.73% | 3.33% | 4.31% |
EPS (Basic) | -1.20 | -3.95 | -1.41 | -3.18 | -1.39 | -0.35 |
EPS (Diluted) | -1.20 | -3.95 | -1.41 | -3.18 | -1.39 | -0.35 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -7.3 | -13.8 | -27.7 | -174.1 | -151.6 | 0.6 |
Free Cash Flow Per Share | -0.08 | -0.15 | -0.31 | -2.10 | -1.88 | 0.01 |
Gross Margin | 68.83% | 69.93% | 69.89% | 68.64% | 70.22% | 71.39% |
Operating Margin | -11.22% | -8.22% | -10.51% | -19.20% | -18.23% | -18.35% |
Profit Margin | -13.96% | -44.38% | -15.20% | -34.96% | -16.51% | -3.94% |
Free Cash Flow Margin | -0.91% | -1.67% | -3.31% | -23.11% | -22.35% | 0.09% |
EBITDA | -40.3 | -14.1 | -26.8 | -82.7 | -71 | -63.9 |
EBITDA Margin | -5.00% | -1.71% | -3.20% | -10.98% | -10.47% | -9.25% |
D&A For EBITDA | 50.2 | 53.7 | 61.2 | 61.9 | 52.7 | 62.8 |
EBIT | -90.5 | -67.8 | -88 | -144.6 | -123.7 | -126.7 |
EBIT Margin | -11.22% | -8.22% | -10.51% | -19.20% | -18.23% | -18.35% |
Revenue as Reported | - | - | - | - | - | 690.6 |
Advertising Expenses | - | 10.1 | 10.3 | 8.5 | 5.3 | - |